[go: up one dir, main page]

WO2019212427A3 - Compositions comprenant de l'erdostéine et de l'acide ascorbique - Google Patents

Compositions comprenant de l'erdostéine et de l'acide ascorbique Download PDF

Info

Publication number
WO2019212427A3
WO2019212427A3 PCT/TR2018/000131 TR2018000131W WO2019212427A3 WO 2019212427 A3 WO2019212427 A3 WO 2019212427A3 TR 2018000131 W TR2018000131 W TR 2018000131W WO 2019212427 A3 WO2019212427 A3 WO 2019212427A3
Authority
WO
WIPO (PCT)
Prior art keywords
erdosteine
ascorbic acid
compositions
expectoration
cough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/000131
Other languages
English (en)
Other versions
WO2019212427A2 (fr
Inventor
Mahmut Bi̇lgi̇ç
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neutec Ar-Ge Sanayi Ve Ticaret AS
Original Assignee
Neutec Ar-Ge Sanayi Ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Ar-Ge Sanayi Ve Ticaret AS filed Critical Neutec Ar-Ge Sanayi Ve Ticaret AS
Publication of WO2019212427A2 publication Critical patent/WO2019212427A2/fr
Publication of WO2019212427A3 publication Critical patent/WO2019212427A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant de l'erdostéine et de l'acide ascorbique à utiliser dans le traitement de l'expectoration et de la toux.
PCT/TR2018/000131 2017-12-30 2018-12-28 Compositions comprenant de l'erdostéine et de l'acide ascorbique Ceased WO2019212427A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/23198 2017-12-30
TR2017/23198A TR201723198A2 (tr) 2017-12-30 2017-12-30 Erdostein ve askorbik asit ihtiva eden kompozisyonlar.

Publications (2)

Publication Number Publication Date
WO2019212427A2 WO2019212427A2 (fr) 2019-11-07
WO2019212427A3 true WO2019212427A3 (fr) 2019-11-28

Family

ID=67900535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/000131 Ceased WO2019212427A2 (fr) 2017-12-30 2018-12-28 Compositions comprenant de l'erdostéine et de l'acide ascorbique

Country Status (2)

Country Link
TR (1) TR201723198A2 (fr)
WO (1) WO2019212427A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035452A1 (fr) * 1995-05-10 1996-11-14 Adcock Ingram Limited Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires
US20020004078A1 (en) * 2000-02-23 2002-01-10 Daniel Gelber Composition and method for treating the effects of diseases and maladies
CA2731454A1 (fr) * 2011-02-10 2012-08-10 Russell Leblanc Composition a base de plantes medicinales et de vitamine c utilisee pour le traitement de l'inflammation et le maintien de la sante
WO2013144976A2 (fr) * 2012-03-28 2013-10-03 Medreich Limited Forme galénique de capsule de gélatine molle à mâcher d'agents mucolytiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035452A1 (fr) * 1995-05-10 1996-11-14 Adcock Ingram Limited Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires
US20020004078A1 (en) * 2000-02-23 2002-01-10 Daniel Gelber Composition and method for treating the effects of diseases and maladies
CA2731454A1 (fr) * 2011-02-10 2012-08-10 Russell Leblanc Composition a base de plantes medicinales et de vitamine c utilisee pour le traitement de l'inflammation et le maintien de la sante
WO2013144976A2 (fr) * 2012-03-28 2013-10-03 Medreich Limited Forme galénique de capsule de gélatine molle à mâcher d'agents mucolytiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAZZANI, G. ET AL.: "In vitro protection by erdosteine against oxidative inactivation of alpha-1-antitrypsin by cigarette smoke", RESPIRATION, vol. 55, no. 2, 1989, pages 113 - 118 *
SIRMALI, M. ET AL.: "Protective effects of erdosteine and vitamins C and E combination on ischemia-reperfusion- induced lung oxidative stress and plasma copper and zinc levels in a rat hind limb model", BIOLOGICAL TRACE ELEMENT RESEARCH, vol. 118, no. 1, 22 May 2007 (2007-05-22) - July 2007 (2007-07-01), pages 43 - 52, XP055657905 *

Also Published As

Publication number Publication date
WO2019212427A2 (fr) 2019-11-07
TR201723198A2 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
ZA202007007B (en) Mcl-1 inhibitors
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2019008696A (es) Compuestos de piridina como inhibidores de shp2 alostericos.
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EP3735976A3 (fr) Utilisation thérapeutique de mitochondries et d'agents mitochondriaux combinés
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
WO2014141210A3 (fr) Cellules souches de pulpe dentaire immatures multifonctionnelles et applications thérapeutiques
PH12017500706B1 (en) Composition containing extract or fraction of genus justicia plant
PH12019501999A1 (en) Pyrazole derivatives as bromodomain inhibitors
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2020007403A (es) Compuestos de tetrahidroisoquinolina.
WO2018094023A3 (fr) Dipeptides cycliques et cicatrisation
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
WO2018105941A3 (fr) Composition pour injection pour la prévention de chute des cheveux ou la stimulation de pousse des cheveux
WO2015156674A3 (fr) Méthode de traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18917426

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18917426

Country of ref document: EP

Kind code of ref document: A2